In depth: Revenue standard is final – A comprehensive look at the new model (Pharmaceutical & Life Sciences industry supplement)

06/19/2014

Download: Revenue standard is final – A comprehensive look at the new model (Pharmaceutical & Life Sciences industry supplement)

This industry-specific supplement to our In depth publication highlights some of the areas that could create the most significant challenges for Pharmaceutical and Life Sciences companies as they transition to the new revenue standard.

Note: Since issuing the new revenue standard in May 2014, the FASB and IASB have proposed various amendments to the guidance. This In depth has not been updated to reflect all of the proposed changes. See In transition US2015-08, The new revenue standard — changes on the horizon, for a summary of the changes, their impact, and the areas where the FASB and IASB have taken different approaches.

The FASB and IASB issued their long-awaited converged standard on revenue recognition on May 28, 2014. Almost all entities will be affected to some extent by the significant increase in required disclosures. But the changes extend beyond disclosures, and the effect on entities will vary depending on industry and current accounting practices.

This industry-specific supplement to our In depth publication highlights some of the more significant impacts to entities within the pharmaceutical and life sciences industry.

For a comprehensive analysis of the new standard, read In depth: Revenue standard is final – A comprehensive look at the new model